ZORN LUDWIG
No ORCID on file
· 77 papers in corpus
· active 2004-2011
Frequent coauthors
- KRUEGER MARTIN 70
- MENRAD ANDREAS 70
- HESS-STUMPP HOLGER 70
- HABEREY MARTIN 70
- HUTH ANDREAS 70
- INCE Stuart 63
- THIERAUCH KARL-HEINZ 49
- THIERAUCH KARL HEINZ 21
- INCE STUAT 14
- WINTERMANTEL TIM 7
2011
The invention relates to selective estrogen receptor modulators (SERMs) and to processes for production thereof, to the use thereof for treatment and/or prophylaxis of disorders, and to the use thereof for production of medicaments for trea…
2011
The invention relates to selective estrogen receptor modulators (SERMs) and to processes for production thereof, to the use thereof for treatment and/or prophylaxis of disorders, and to the use thereof for production of medicaments for trea…
2011
The invention relates to selective estrogen receptor modulators (SERMs) and to processes for production thereof, to the use thereof for treatment and/or prophylaxis of disorders, and to the use thereof for production of medicaments for trea…
2011
The invention relates to selective estrogen receptor modulators (SERMs) and to processes for production thereof, to the use thereof for treatment and/or prophylaxis of disorders, and to the use thereof for production of medicaments for trea…
2011
The invention relates to selective estrogen receptor modulators (SERMs) and to processes for production thereof, to the use thereof for treatment and/or prophylaxis of disorders, and to the use thereof for production of medicaments for trea…
2011
The invention relates to selective estrogen receptor modulators (SERMs) and to processes for production thereof, to the use thereof for treatment and/or prophylaxis of disorders, and to the use thereof for production of medicaments for trea…
2011
The invention relates to selective estrogen receptor modulators (SERMs) and to processes for production thereof, to the use thereof for treatment and/or prophylaxis of disorders, and to the use thereof for production of medicaments for trea…
2009
VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridinamides, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis, as well as intermediate products for the production of the c…
2009
VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridinamides, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis, as well as intermediate products for the production of the c…
2009
VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridinamides, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis, as well as intermediate products for the production of the c…
2009
VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridinamides, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis, as well as intermediate products for the production of the c…
2009
VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridinamides, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis, as well as intermediate products for the production of the c…
2009
VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridinamides, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis, as well as intermediate products for the production of the c…
2009
VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridinamides, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis, as well as intermediate products for the production of the c…
2009
VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridinamides, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis, as well as intermediate products for the production of the c…
2009
VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridinamides, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis, as well as intermediate products for the production of the c…
2009
VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridinamides, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis, as well as intermediate products for the production of the c…
2009
VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridinamides, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis, as well as intermediate products for the production of the c…
2009
VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridinamides, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis, as well as intermediate products for the production of the c…
2009
VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridinamides, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis, as well as intermediate products for the production of the c…
2009
VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridinamides, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis, as well as intermediate products for the production of the c…
2007
VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridinamides, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis, as well as intermediate products for the production of the c…
2007
VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridinamides, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis, as well as intermediate products for the production of the c…
2007
VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridinamides, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis, as well as intermediate products for the production of the c…
2007
VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridinamides, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis, as well as intermediate products for the production of the c…